U.S. Markets closed

bioAffinity Technologies, Inc. (BIAF)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
0.00000.0000 (0.00%)
At close: 08:00PM EDT

bioAffinity Technologies, Inc.

22211 West Interstate 10
Suite 1206
San Antonio, TX 78257
United States
210 698 5334

IndustryDiagnostics & Research
Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Ms. Maria Zannes J.D.Founder, Pres, CEO & Director227.2kN/A1956
Dr. Vivienne I. Rebel M.D., Ph.D.Exec. VP and Chief Medical & Science Officer236.59kN/A1965
Mr. Michael Edwards CPA, M.B.A.Chief Financial OfficerN/AN/A1967
Mr. Xavier T. Reveles M.S.VP of OperationsN/AN/AN/A
Mr. Timothy P. Zannes J.D.Exec. VP, Sec. & Gen. CounselN/AN/A1953
Dr. William Bauta Ph.D.Sr. VP of R&D - TherapeuticsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

Corporate Governance

bioAffinity Technologies, Inc. ’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.